Heterogeneity of TP53-mutated myeloid malignancies and association with relative clinical outcomes
| Variable . | Relatively favorable outcome . | Poor outcome . | Comments/caveats . |
|---|---|---|---|
| Mutation type | Missense | Truncating only | Underpowered; did not account for all transplant-relevant covariates |
| VAF | Low | High | VAF is imprecise → reflects composite of ploidy and purity/clone size; difficult to define a generalized cut point |
| Allelic state | Single | Multi | Only shown in nontransplant MDS; not tested in HCT context |
| Karyotype | Noncomplex | Complex | |
| Response to treatment | MRD-negative CR | MRD-positive, active disease | Conflicting data |
| Clinical ontogeny | - | - | No apparent impact of secondary vs therapy-related vs de novo disease |
| Germline predisposition | - | - | Certain germline leukemia predispositions are associated with development of somatic TP53 mutations (Shwachman-Diamond syndrome, telomere biology disorders, etc). |
| Variable . | Relatively favorable outcome . | Poor outcome . | Comments/caveats . |
|---|---|---|---|
| Mutation type | Missense | Truncating only | Underpowered; did not account for all transplant-relevant covariates |
| VAF | Low | High | VAF is imprecise → reflects composite of ploidy and purity/clone size; difficult to define a generalized cut point |
| Allelic state | Single | Multi | Only shown in nontransplant MDS; not tested in HCT context |
| Karyotype | Noncomplex | Complex | |
| Response to treatment | MRD-negative CR | MRD-positive, active disease | Conflicting data |
| Clinical ontogeny | - | - | No apparent impact of secondary vs therapy-related vs de novo disease |
| Germline predisposition | - | - | Certain germline leukemia predispositions are associated with development of somatic TP53 mutations (Shwachman-Diamond syndrome, telomere biology disorders, etc). |